Verrica Pharmaceuticals Inc. Announces Annual Meeting of Stockholders on June 6, 2024

TL;DR

<b>Verrica Pharmaceuticals Inc. will hold its Annual Meeting of Stockholders on June 6, 2024, to elect directors, vote on executive compensation, and ratify the independent auditor.</b>

AI Summary

Verrica Pharmaceuticals Inc. (VRCA) filed a Proxy Statement (DEF 14A) with the SEC on April 19, 2024. Annual Meeting of Stockholders scheduled for June 6, 2024, at 10:00 a.m. local time. Nominees Ted White and Mark Prygocki are up for election to the Board of Directors. Stockholders will vote on an advisory basis for executive compensation. The frequency of future advisory votes on executive compensation will be indicated. KPMG LLP is proposed for ratification as the independent registered public accounting firm for FY2024.

Why It Matters

For investors and stakeholders tracking Verrica Pharmaceuticals Inc., this filing contains several important signals. The election of directors and advisory votes on executive compensation are key governance matters that directly impact shareholder oversight and alignment with management. Ratification of the independent auditor is crucial for maintaining financial transparency and investor confidence in the company's financial reporting.

Risk Assessment

Risk Level: low — Verrica Pharmaceuticals Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would alter the company's risk profile.

Analyst Insight

Stockholders should review the nominees for the Board of Directors and the advisory proposals on executive compensation before the June 6, 2024 meeting.

Key Numbers

• June 6, 2024 — Annual Meeting Date (Date of the Annual Meeting of Stockholders)
• April 12, 2024 — Record Date (Record date for determining stockholders entitled to vote)
• 2027 — Director Term End (Term end year for elected directors)
• December 31, 2024 — Fiscal Year End (Fiscal year end for independent auditor ratification)

Key Players & Entities

• Verrica Pharmaceuticals Inc. (company) — Registrant
• Ted White (person) — Nominee for Board of Directors
• Mark Prygocki (person) — Nominee for Board of Directors
• KPMG LLP (company) — Independent registered public accounting firm
• Christopher G. Hayes (person) — Secretary

FAQ

Industry Context

Verrica Pharmaceuticals Inc. operates in the pharmaceutical preparations industry, focusing on developing and commercializing treatments for skin diseases.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934, specifically Schedule 14A, which governs the solicitation of proxies.

What Investors Should Do

1. Review the biographies and qualifications of director nominees Ted White and Mark Prygocki.
2. Understand the company's executive compensation practices and the advisory vote proposal.
3. Confirm the ratification of KPMG LLP as the independent auditor for fiscal year 2024.

Key Dates

• 2024-06-06: Annual Meeting of Stockholders — Election of directors, advisory votes on executive compensation, and ratification of auditor.
• 2024-04-19: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.
• 2024-04-12: Record Date — Date to determine which stockholders are entitled to vote at the Annual Meeting.

Year-Over-Year Comparison

This is the initial filing for the 2024 Annual Meeting of Stockholders, providing details on upcoming proposals and meeting logistics.

Filing Documents

• d18791ddef14a.htm (DEF 14A) — 383KB
• g18791dsp047.jpg (GRAPHIC) — 178KB
• g18791dsp048.jpg (GRAPHIC) — 125KB
• g18791g02a02.jpg (GRAPHIC) — 31KB
• g18791g22b02.jpg (GRAPHIC) — 51KB
• g18791g38a01.jpg (GRAPHIC) — 50KB
• g18791g39a01.jpg (GRAPHIC) — 81KB
• g18791g45a45.jpg (GRAPHIC) — 53KB
• 0001193125-24-101650.txt (&nbsp;) — 1161KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 23

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 25 S UMMARY C OMPENSATION T ABLE 25 O UTSTANDING E QUITY A WARDS AS OF D ECEMBER 31, 2023 26 N ARRATIVE TO S UMMARY C OMPENSATION T ABLE 27 E QUITY -B ASED A WARDS 28 E MPLOYMENT A RRANGEMENTS AND P OTENTIAL P AYMENTS UPON T ERMINATION OF E MPLOYMENT OR C HANGE IN C ONTROL 29 R ETIREMENT B ENEFITS AND O THER C OMPENSATION 31 PAY VERSUS PERFORMANCE 32 DIRECTOR COMPENSATION 36 N ON -E MPLOYEE D IRECTOR C OMPENSATION P OLICY 36 SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS 38 TRANSACTIONS WITH RELATED PERSONS 39 R ELATED -P ERSON T RANSACTIONS P OLICY AND P ROCEDURES 39 C ERTAIN R ELATED P ARTY T RANSACTIONS 39 HOUSEHOLDING OF PROXY MATERIALS 41 OTHER MATTERS 41 i Table of Contents VERRICA PHARMACEUTICALS INC. 44 W. Gay St., Suite 400 West Chester, Pennsylvania 19380 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held on June 6, 2024 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a notice regarding the availability of proxy materials on the internet? Pursuant to rules adopted by the Securities and Exchange Commission (the SEC), we have elected to provide access to our proxy materials over the internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials (the Notice) because the Board of Directors (Board or Board of Directors) of Verrica Pharmaceuticals Inc. (sometimes referred to as the Company or Verrica) is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders, including at any adjournments or postponements of the meeting. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the internet or to request a printed copy may be found in the Notice. We intend to mail the Notic

View Full Filing

View this DEF 14A filing on SEC EDGAR